US comes up with two mandatory IRP use pricing models under Trump’s MFN strategy
Just before Christmas 2025, the US Centers for Medicare and Medicaid Services (CMS) unveiled two pricing models based on the …
Post
-
-
Managing supply chain challenges for CDMOs
Pharma supply chains are under enormous pressure globally, with geopolitical tensions and the issue of tariffs requiring careful management by …
-
Alveus debuts in obesity arena with $160m Series A
Alveus Therapeutics has debuted with $160m in Series A financing, as the biotech looks to join the crowded obesity sector …
-
J&J cuts MFN deal with the Trump administration, bolsters US onshoring efforts
Johnson & Johnson (J&J) has become the latest in a stream of pharma companies to sign a drug pricing deal …
-
Takeda and Halozyme sign global agreement for Enhanze technology
Takeda has announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the latter’s Enhanze drug …
-
Bile acid modulators in discovery: Identifying cholestasis candidates with the best chance of success
Disrupted bile flow, or cholestasis, is a key feature of various chronic liver diseases such as primary biliary cholangitis (PBC) …
-
Santhera grants Agamree rights to Nxera for DMD
Santhera Pharmaceuticals has entered an exclusive licensing agreement with Nxera Pharma for Agamree (Vamorolone) to treat Duchenne muscular dystrophy (DMD) …
-
Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn
Eli Lilly has agreed to acquire autoimmune oral drug developer Ventyx Biosciences, representing the big pharma company’s latest push to …
-
GSK to file for approval of twice-yearly hep B drug on positive Phase III data
GSK’s six-monthly triple-action investigational antisense oligonucleotide (ASO) candidate has demonstrated a clinically and statistically significant functional cure in chronic hepatitis …
-
Octapharma receives FDA approval for new Fibryga formulation in AFD
Octapharma has received approval from the US Food and Drug Administration (FDA) for a new 2-gram (g) formulation of Fibryga …
-
Day One concludes Mersana Therapeutics acquisition
Day One Biopharmaceuticals has concluded its acquisition of Mersana Therapeutics after meeting all the tender offer conditions. The tender offer expired …
-
Amgen buys Dark Blue Therapeutics in $840m oncology deal
Amgen has agreed to acquire UK-based biotech Dark Blue Therapeutics for up to $840m, making it the first pharma takeover …
-
Eli Lilly signs $1.3bn obesity-focused research deal with Nimbus
Eli Lilly has signed a research and licence agreement with Nimbus Therapeutics, aiming to develop a new oral weight loss …
-
Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis
Cellenkos has received orphan drug designation from the US Food and Drug Administration (FDA) for its investigational CK0804 regulatory T …
-
Zai Lab’s Augtyro receives NMPA approval for solid tumours in China
Zai Lab has received approval from China’s National Medical Products Administration (NMPA) for the supplemental new drug application (sNDA) for …
